Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK.
Damm-Welk C, Siddiqi F, Fischer M, Hero B, Narayanan V, Camidge DR, Harris M, Burke A, Lehrnbecher T, Pulford K, Oschlies I, Siebert R, Turner S, Woessmann W. Damm-Welk C, et al. Among authors: hero b. J Cancer. 2016 Jun 30;7(11):1383-7. doi: 10.7150/jca.15238. eCollection 2016. J Cancer. 2016. PMID: 27471553 Free PMC article.
Histone deacetylase 8 in neuroblastoma tumorigenesis.
Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, von Deimling A, Fischer M, Witt O. Oehme I, et al. Among authors: hero b. Clin Cancer Res. 2009 Jan 1;15(1):91-9. doi: 10.1158/1078-0432.CCR-08-0684. Clin Cancer Res. 2009. PMID: 19118036
Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.
Ackermann S, Goeser F, Schulte JH, Schramm A, Ehemann V, Hero B, Eggert A, Berthold F, Fischer M. Ackermann S, et al. Among authors: hero b. Clin Cancer Res. 2011 Feb 15;17(4):731-41. doi: 10.1158/1078-0432.CCR-10-1129. Epub 2010 Dec 17. Clin Cancer Res. 2011. PMID: 21169242
High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma.
Schulte JH, Bachmann HS, Brockmeyer B, Depreter K, Oberthür A, Ackermann S, Kahlert Y, Pajtler K, Theissen J, Westermann F, Vandesompele J, Speleman F, Berthold F, Eggert A, Brors B, Hero B, Schramm A, Fischer M. Schulte JH, et al. Among authors: hero b. Clin Cancer Res. 2011 Aug 1;17(15):5082-92. doi: 10.1158/1078-0432.CCR-10-2809. Epub 2011 Jun 1. Clin Cancer Res. 2011. PMID: 21632861
192 results